Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02573766 : Neuromodulation as a Treatment for Chemotherapy-Induced Peripheral Neuropathy
PhaseN/A
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

1. Patients must have the ability to understand and read English, sign a written
informed consent, and be willing to follow protocol requirements.

2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.

3. Pain score >/= 4 on a 0-10 numeric pain scale and/or grade 3 neuropathic symptoms
according to the National Cancer Institute's 4 point grading scale.

4. Neuropathic symptoms must be related to chemotherapy (in the opinion of the treating
physician).

5. Patients must have had neuropathic pain for a minimum of 3 months.

6. No plans to change pain medication regimen during the course of the study.

7. Off active chemotherapy treatment for minimum of 6 months.

8. Hormonal (e.g., tamoxifen or arimidex, etc.) and targeted (tarceva and avastin, etc.)
therapies allowed as long as they will be continued during the course of the study.

9. Willing to come to MD Anderson for the therapy sessions; or willing to participate in
the therapy sessions at their homes and live within a 45 minute drive of MDA main
campus; or can participate in the therapy sessions from one of MDA's Regional Care
Centers.

10. Patients who are 18 years of age or above

11. Patients who have a diagnosis of breast cancer.

Exclusion Criteria:

1. Patients who are taking any antipsychotic medications.

2. Patients with active central nervous system (CNS) disease, such as clinically-evident
metastases or leptomeningeal disease, dementia, or encephalopathy.

3. Patients who have ever been diagnosed with bipolar disorder or schizophrenia.

4. Patients with known, previously diagnosed peripheral neuropathy from causes other
than chemotherapy.

5. Patients who have a history of head injury or who have known seizure activity.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02573766      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740